Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical trials

ART: ARTERIAL REVASCULARISATION TRIAL

ART compares single internal mammary artery grafting (SIMA) with bilateral internal mammary artery grafting (BIMA) in patients undergoing coronary artery bypass graft surgery. 3102 patients were randomised and will be followed for 10 years.

Doug Altman and Stephen Gerry

BIOMARKERMB 

This trial investigates the use of a biomarker in a routine blood test to provide personalised or stratified medicines to chronic obstructive pulmonary disease (COPD) patients. Its results have the potential to change clinical practice.

Sharon Love and Lei Clifton

FUROHF: INHALED FUROSEMIDE FOR DYSPNOEA RELIEF

Patients with advanced heart failure often experience a distressing shortness of breathe, called dyspnoea. FUROHF tests whether furosemide, a diuretic commonly used to treat oedema, will help in symptom relief for these patients.

Susan Dutton and Lei Clifton

GOLD-PCI: Investigate the Protective Effects of Glucagon-like Peptide-1 (GLP-1) in Patients Undergoing Elective Angioplasty and Stenting

When the coronary arteries narrow or block, metal tubes are placed in the arteries using balloon inflation to improve the blood supply to the heart, a procedure called coronary angioplasty and stenting. The heart muscle downstream of the balloon can be damaged in this procedure.

Glucagon-like peptide 1 (GLP 1) is a naturally occurring hormone secreted by cells in the gut in response to food. It stimulates the pancreas to release insulin and the heart muscle to absorb glucose. GLP−1 protects the heart and improves heart muscle performance in people with coronary artery disease. GOLD-PCI tests whether it can also protect the heart during coronary angioplasty and stenting.

Sharon Love and Lei Clifton

OXVALVE: BURDEN OF UNDIAGNOSED VALVULAR HEART DISEASE IN OLDER PEOPLE:  THE OXVALVE POPULATION COHORT STUDY 

OXVALVE logoDegenerative valvular heart disease (VHD) is likely to become a more frequent and important public health problem, leading to increasing demand on healthcare resources. Reliable estimates of the prevalence of VHD in high-income countries are constrained by the design of previous studies. OXVALVE measures the prevalence of newly diagnosed VHD in a population-based cohort of unselected older people and quantifies the severity and sub-types of the disease.

Jacqueline Birks and Eleni Frangou

TEPHRA: TRIAL OF EXERCISE TO PREVENT HYPERTENSION IN YOUNG ADULTS

TEPHRA logoTEPHRA investigates whether exercise can reduce blood pressure in young adults who were born prematurely. It will also compare the angiogenic and vascular training adaptations in young adults born prematurely or full-term.

Sharon Love and Eleni Frangou

UK TAVI: THE UNITED KINGDOM TRANSCATHETER AORTIC VALVE IMPLANTATION 

UK TAVI logoUK TAVI is a multi-centre trial comparing the clinical effectiveness and cost-utility of TAVI and conventional surgical aortic valve replacement in patients with severe symptomatic aortic stenosis. This SITU trial is sponsored by the University of Leicester.

Doug Altman, Susan Dutton, and Virginia Chiocchia